Alpha Tau Medical Ltd.DRTS
Price (close)
$14.54
Market cap
$1.3B
P/E
—
Revenue (FY)
—
Net income
-$42.6M
Dividend yield
—
1-year total return
249.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Alpha Tau Medical Ltd. does.
therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as
a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT ® technology is designed to utilize the specific
therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$8.9M | -$27.3M | -$33.8M | -$29.2M | -$31.8M | -$42.6M |
| Free cash flow | -$11.0M | -$14.7M | -$24.8M | -$24.4M | -$22.0M | -$32.8M |
More on DRTS.
- Alpha Tau Medical Ltd. summary
- Alpha Tau Medical Ltd. financial statements
- Alpha Tau Medical Ltd. key metrics
- Alpha Tau Medical Ltd. health scores and style box
- Alpha Tau Medical Ltd. earnings
- Alpha Tau Medical Ltd. dividends
- Alpha Tau Medical Ltd. valuation
- Alpha Tau Medical Ltd. ownership and insiders
- Alpha Tau Medical Ltd. peers
Figures from Alpha Tau Medical Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.